Please ensure Javascript is enabled for purposes of website accessibility

Oral Multiple Sclerosis Drugs Heat Up

By Brian Orelli, PhD - Updated Apr 6, 2017 at 10:06PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Watch out Novartis and Gilenya.

Novartis (NYSE: NVS) currently has the oral multiple sclerosis drug market all to itself. Gilenya is the only drug that's taken orally to treat the progression of the disease. All the other drugs have to be injected or infused.

Technically, Acorda Therapeutics' (Nasdaq: ACOR) Ampyra also doesn't require needles, but it's designed to treat one of the symptoms of multiple sclerosis -- the inability to walk – and it doesn't treat the progression of the disease.

Unfortunately for Novartis, it looks like Gilenya's competition-free period will vanish in the not-too-distant future.

The most advanced is Merck KGaA's Movectro, but it may not be the next on the market. The German company pulled its EU application after it was clear regulators there would rebuff the drug. The Food and Drug Administration followed suit, turning down the drug last month.

In the pipeline
Last week, Biogen Idec (Nasdaq: BIIB) shared some details from its phase 3 trial of its oral multiple sclerosis drug, BG-12. The biotech had already said the trial passed, but the level of efficacy was quite impressive. BG-12 cut the annualized relapse rate by 53% and reduced disability progression by 38%.

Teva Pharmaceutical (Nasdaq: TEVA) also has an oral multiple sclerosis drug that's read out a phase 3 clinical trial, but on the surface, the data don't look as good. Laquinimod cut the annualized relapse rate by 23% in its most recently released data and reduced disability progression by 36%.

Adding to the mix, sanofi-aventis (NYSE: SNY) also has an oral multiple sclerosis drug, teriflunomide. In a phase 3 trial, the drug cut the annualized relapse rate by 31% and the disability progression by 30%.

The only way to know for sure which drug is better is for one of the companies to run a head-to-head clinical trial, but the data certainly seem to favor BG-12 with the substantial decrease in the annualized relapse rate.

Big competition
The fight investors should be keeping their eye on is between oral drugs and those that need to be injected or infused. There's an awful lot of revenue at stake among the current needle-requiring drugs.

Teva's Copaxone is a $3.3 billion drug and Biogen's Avonex wasn't that far behind at $2.5 billion last year. Pfizer (NYSE: PFE) and Merck KGaA have Rebif, and there's also Bayer's Betaseron.

My guess is that Tysabri, sold by Biogen and Elan (NYSE: ELN), will be safe from immediate competition. Because of potential side effects -- a potentially deadly brain infection -- Tysabri is primarily used as a secondary treatment. The oral medications are likely to be used as a first-line treatment for needle-phobic patients.

What's an investor to do?
The only pure play on multiple sclerosis is Acorda. Biogen and Elan are close, with multiple sclerosis drugs making up a majority of their options. If you're going to invest in the rest, you'll need to like their additional offerings as well.

At the moment, Biogen seems to be the best bet for driving sales forward. Coming to market after Gilenya won't be so bad; Novartis will have done the leg work, prepping doctors for the next-generation of multiple sclerosis drugs. BG-12 will likely cannibalize sales of Biogen's Avonex, but there's plenty of additional patients to steal from competing injectable drugs as well.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sanofi Stock Quote
Sanofi
SNY
$53.42 (5.95%) $3.00
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$51.59 (3.00%) $1.50
Novartis AG Stock Quote
Novartis AG
NVS
$84.83 (3.63%) $2.97
Elan Corporation Limited Stock Quote
Elan Corporation Limited
ELN
Biogen Inc. Stock Quote
Biogen Inc.
BIIB
$211.93 (0.26%) $0.55
Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
TEVA
$7.74 (0.91%) $0.07
Acorda Therapeutics, Inc. Stock Quote
Acorda Therapeutics, Inc.
ACOR
$0.52 (-7.13%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
321%
 
S&P 500 Returns
111%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.